drugset / Trial / NCT04252885

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

NCT04252885

Phase 4 Completed 86 enrolled Guangzhou 8th People's Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The study explores the efficacy of lopinavir plus ritonavir and arbidol in treating with novel coronavirus infection. As a result this study would provide evidence for the clinical usage of these drugs in the future .

Timeline

Start
2020-01-28
Primary completion
2020-04-30
Completion
2020-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lopinavir Other / unclassified 200 mg Oral
Subject Ritonavir Other / unclassified 50 mg Oral
Comparator Umifenovir Small molecule 200 mg Oral